The transdermal 7-day buprenorphine patch - An effective and safe treatment option, if tramadol or tilidate/naloxone is insufficient. Results of a non-interventional study;7-tage-pflaster mit buprenorphin - Eine option, wenn die therapie mit tramadol bzw. tilidin/naloxon unzureichend ist: Ergebnisse einer nicht interventionellen studie

MMW-Fortschritte der Medizin

Volumn 152, Issue SUPPL. 2, 2010, Pages 62-69

  Schutter, Ulf ^a   Ritzdorf, Ingrif ^b   Heckes, Birgit ^b  

^a Spezielle Schmerztherapie Palliativmedizin Notfallmedizin ^*  (Germany)

^b GRÜNENTHAL GMBH   (Germany)

Author keywords

Buprenorphine; Matrix patch; Musculoskeletal pain; Pain; Previous opioid treatment

Indexed keywords

BUPRENORPHINE; NALOXONE; TILIDINE; TRAMADOL;

ANALGESIA; ARTICLE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MUSCULOSKELETAL PAIN; PAIN ASSESSMENT; PATIENT COMPLIANCE; QUALITY OF LIFE; SLEEP; TREATMENT DURATION;

ACTIVITIES OF DAILY LIVING; ADMINISTRATION, CUTANEOUS; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; BUPRENORPHINE; CHRONIC DISEASE; DRUG SUBSTITUTION; FEMALE; GERMANY; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; NALOXONE; PAIN; PAIN MEASUREMENT; PROSPECTIVE STUDIES; QUALITY OF LIFE; TILIDINE; TRAMADOL;

EID: 77954512286     PISSN: 14383276     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Caplan, R. A., Southam, M.: Transdermal drug delivery and its application to pain control. Adv. Pain Res. Ther. 14 (1990), 233-240.
2. Fachinformation Norspan® Stand 03/2009.
3. Budd, K.: Buprenorphine and the transdermal system: The ideal match in pain management. Int. J. Clin. Pract. Suppl. 133 (2003), 9-14.
4. Gardner-Nix, J.: Principles of opioid use in chronic non-cancer pain. CMAJ 169 (2003), 38-43. (Pubitemid 36898076)
5. Heckes, B., Ritzdorf, I.: Wirksamkeit und Sicherheit eines Buprenorphin-haltigen 7-Tage Pflasters (Norspan®) bei chronischen opioid pflichtigen Schmerzen. Schmerz 23 (Suppl. 1) (2009), 67 Abstract PO7.5.
6. Höer, A., Kurepkat, M., Gottberg, A., Häussler, B.: Transdermale und orale Opioide in der ambulanten Schmerztherapie. Schmerz 22 (2008), 156-163.
7. http://www.gesundheitsforschung-bmbf.de/de/139.php.
8. Ickowicz, E.: Pharmacological management of persitent pain in older persons. JAGS 57 (2009), 1331-1346.
9. Likar, R.: Safety of pain management with transdermal buprenorphine. Ther. Clin. Risk Manag. 2 (2006), 115-125.
10. Moore, R. A., Sear, J. W., McQuay, H. J.: Renal failure: Effects on morphine and buprenorphine kinetics in man. Pain 2 (1994), S398.
11. Ohnhaus, E. E.: Arzneimittelwechselwirkungen durch Beeinflussung der Plasmaeiweißbindung. Internist (Berl) 20 (1979), 225-228.
12. Reidenberg, B., Eltahtawy, A., Munera, C., Cipriano, A., Tonelli, A., Reder, R.: Daily pharmacokinetic performance of a buprenorphine transdermal system (BTDS) for up to 7 days. J. Clin. Pharmacol. 41 (2001), 1027.
13. Schutter, U., Ritzdorf, I., Heckes, B.: Chronische Arthroseschmerzen: Effektivität und Verträglichkeit eines 7-Tage-Pflasters mit niedrig dosiertem Buprenorphin. MMW Fortschr. Med. 150 (Orig.) (2008), 96-103.
14. Sittl, R., Nuitjen, M., Nautrup, B. P.: Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and non-cancer pain: Results of a retrospective cohort study. Clin. Ther. 27 (2005), 1022-1031.
15. Spyker, D. A., Hale, M., Munera, C. L., Wright, C.: Effectiveness and safety of buprenorphine transdermal system (BTDS) compared with hydrocodone/acetaminophen in the treatment of patients with chronic low back pain. Program and abstracts of the 21st Annual Scientific Meeting of the American Pain Society; March 14-17, 2002; Baltimore, Maryland. J. Pain 3 (2002), 14, Abstract 653.
16. Spyker, D. A., St Ville, J., Lederman, M., Munera, C. L., Wright, C.: Analgesic efficacy and safety of buprenorphine transdermal system (BTDS) in patients with osteoarthritis. Program and abstracts of the 21st Annual Scientific Meeting of the American Pain Society; March 14-17, 2002; Baltimore, Maryland. J. Pain 3 (2002), 2, Abstract 645.